News

Royalty Pharma published press releases by date and/or category

Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million

NEW YORK, NY and SOUTH SAN FRANCISCO, CA, January 7, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Cytokinetics has secured long-term capital from Royalty Pharma to support the potential commercialization of omecamtiv

Royalty Pharma Announces 12% Dividend Increase

Earnings

NEW YORK, NY, January 6, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of $0.19 per Class A share, reflecting a 12% increase in the company’s quarterly dividend over the previous quarter’s dividend.

Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10

Events

NEW YORK, NY, January 5, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at

Royalty Pharma to Present at Evercore ISI 4th Annual Healthconx Virtual Conference

Events

NEW YORK, NY, November 29, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4 th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET. The webcast will be accessible from Royalty Pharma’s

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and Orladeyo from Biocryst Pharmaceuticals

Transactions

NEW YORK, NY and RESEARCH TRIANGLE PARK, NC, November 22, 2021 – Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

Royalty Pharma Reports Third Quarter 2021 Results

Earnings

NEW YORK, NY, November 10, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾(a non-GAAP financial measure).

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

Earnings

NEW YORK, NY, October 18, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

Earnings

NEW YORK, NY, October 15, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record at the close of business

Royalty Pharma to Present at Upcoming Investor Conferences

Events

NEW YORK, NY, September 3, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m.

Royalty Pharma Reports Second Quarter 2021 Results

Earnings

NEW YORK, NY, August 11, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts⁽¹⁾(a non-GAAP financial measure).

News

Stay up to date